Pfizer (PFE) Stock Jumps Today—Is It Time to Buy Before the Next Breakout?

October 6, 2025 — Pfizer Inc. (NYSE: PFE) is back on traders’ radar after a flurry of catalysts lifted sentiment and nudged the long-lagging share price higher. Intraday price action PFE stock opened Monday at $27.40 and traded in a narrow $27.12-$27.68 band by midday, extending last week’s 1% advance that snapped a multi-week losing streak. The shares closed Friday at $27.37, valuing the drugmaker at roughly $156 billion. Why the tide is turning • White House pricing accord: On October 1 Pfizer announced a “most-favored-nation” deal with the Biden administration that locks in reduced prescription costs, easing regulatory overhang and sparking a sector-wide rally. • Dividend magnet: At Friday’s close the forward yield hovered near 5.6%, one of the highest among Big Pharma peers, attracting income investors. • Pipeline momentum: Management reiterated plans to file or launch at least eight blockbuster candidates by 2027, targeting oncology, RSV and obesity — areas of robust demand. What Wall Street expects The consensus 12-month price target sits at $28.63, implying 5-6% upside from current levels, with bulls citing cost synergies from the Seagen acquisition and resurgent COVID/RSV franchise revenue. Bears argue that patent cliffs on Eliquis and Ibrance still cap valuation multiples. Key metrics to watch this quarter • Q3 revenue projection: $14.2 billion • Adjusted EPS: $0.69 • R&D spend: ~$3 billion • Net debt-to-EBITDA: 1.1× Trading outlook Technicians note that PFE stock is testing resistance at its 50-day moving average near $27.80; a decisive break could open room toward the $30 psychological zone. Conversely, support sits around the October low of $26.50. Bottom line After two years of underperformance, PFE stock finally has near-term catalysts — a favorable pricing deal, rich dividend and deep pipeline — that could reignite investor interest. Whether momentum sticks will hinge on upcoming earnings and management’s ability to execute on post-COVID growth plans.